Off-Label Use of Atypical Antipsychotics: An Update
Conclusions (2 of 3)
The evidence for efficacy of atypical antipsychotics in treating borderline personality disorders is too limited to estimate benefits.
Evidence is insufficient for treatment of Tourette’s syndrome in adults (ages 18–64).
Evidence is stronger that atypical antipsychotics neither increase body weight in patients with anorexia nervosa nor do they reduce substance abuse.
There is little evidence about optimal dosages or durations of treatment in off-label use.
Keywords: antipsychotics | atypical antipsychotics | off-label | second generation | extrapyramidal symptoms | mortality | adverse effects | anorexia nervosa | substance abuse | sedation | fatigue | weight
- Maglione M, Ruelaz Maher A, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness Review No. 43 (Prepared by the Southern California RAND Evidence-based Practice Center under Contract No. HHSA 290-2007-10062-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11(12)-EHC087-EF. Available at www.effectivehealthcare.ahrq.gov/offlabelantipsych.cfm.
Your slide tray is being processed.